This information was originally presented at the NCCN 12th Annual Congress: Hematologic Malignancies™ held in San Francisco, California, on October 6-7, 2017.

This information was originally presented at the NCCN 2017 Nursing Forum: Oncology Nursing in Hematologic Malignancies held in San Francisco, California, on October 6, 2017.

This information was originally presented at the NCCN 11^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This information was originally presented at the NCCN 11^th Annual Congress: Hematologic Malignancies™ held in New York, New York.

This activity is designed to address the unprecedented recent and ongoing advances in AML research and anticipated changes in the AML therapeutic landscape resulting from the development of many innovative therapies, several of which are in late stages of clinical trials.  The goal of this activi

This activity is designed to address the unprecedented recent and ongoing advances in AML research and anticipated changes in the AML therapeutic landscape resulting from the development of many innovative therapies, several of which are in late stages of clinical trials.  The goal of this activi

This information was originally presented at the NCCN 10^th Annual Congress: Hematologic Malignancies™ held in San Francisco, California.

Old age (≤65 years), relapsed or refractory disease, and the presence of FMS-like receptor tyrosine kinase-3 (FLT3) internal tandem duplication (ITD) mutation are poor prognostic factors in acute myeloid leukemia (AML).

Progressive multifocal leukoencephalopathy (PML) is a rare fatal complication of allogeneic bone marrow transplantation (BMT) resulting from chronic immunosuppression and impaired cellular immunity.

This information was originally presented on September 20, 2014, at the NCCN 9th Annual Congress: Hematologic Malignancies™ held in New York, New York.